论文部分内容阅读
目的观察胸腺肽联合阿德福韦酯治疗慢性乙型病毒性肝炎(乙肝,HBV)的临床疗效。方法慢性乙肝患者60例,分为治疗组30例,采用胸腺肽10 mg,3次/d,口服,每周2次,共用6个月,同时加用阿德福韦酯10 mg,1次/d,口服,共1年;对照组30例,仅用阿德福韦酯10 mg,1次/d,口服,共1年。结果治疗组在治疗6、12个月时丙氨酸氨基转移酶(ALT)复常率、HBeAg阴转率、HBeAg/抗-HBe血清转换率明显优于对照组,而在HBV-DNA阴转率方面两组差异无统计学意义。结论胸腺肽联合阿德福韦酯治疗慢性乙肝的ALT复常率、HBeAg阴转率、HBeAg/抗-HBe血清转换率明显优于阿德福韦酯。
Objective To observe the clinical efficacy of thymosin combined with adefovir dipivoxil in the treatment of chronic hepatitis B (hepatitis B, HBV). Methods Sixty patients with chronic hepatitis B were divided into treatment group (n = 30), thymosin 10 mg, orally, twice a week for 6 months, plus adefovir dipivoxil 10 mg once daily, d, orally, a total of 1 year; control group of 30 patients, only adefovir dipivoxil 10 mg, 1 / d, orally for a total of 1 year. Results The ALT normalization rate, HBeAg negative conversion rate and HBeAg / anti-HBe conversion rate in the treatment group were significantly better than those in the control group at 6 and 12 months. However, There was no significant difference in rates between the two groups. Conclusions Thymosin combined with adefovir dipivoxil treatment of chronic hepatitis B ALT normalization rate, HBeAg negative conversion rate, HBeAg / anti-HBe seroconversion rate was significantly better than adefovir dipivoxil.